Hangzhou‑based Chance Pharmaceuticals Co., Ltd. has inked an exclusive commercialization agreement with Shanghai‑listed Huadong Medicine (SHE: 000963) for its advanced budesonide/formoterol dry‑powder inhaler, CXG87. The deal positions CXG87 as the sole product that Chance will develop, register and supply in mainland China, while Huadong will spearhead marketing and promotion.
Key Deal Highlights
- Exclusive Commercial Rights – Chance Pharma acts as the Marketing Authorization Holder (MAH), responsible for R&D, registration, production and supply.
- Financial Structure – Chance receives an upfront payment plus milestone‑linked payments tied to regulatory approval and sales targets.
- Partner Role – Huadong Medicine will handle all commercialization activities, leveraging its established distribution network across China.
Product Edge
- Category 2.2 Modified Drug – CXG87 is an independently developed formulation specifically optimized for respiratory conditions, notably asthma.
- Superior Performance – Compared with AstraZeneca’s Symbicort Turbuhaler, CXG87 offers more stable therapeutic efficacy and enhanced patient convenience.
- Clinical Milestones – Phase 3 enrollment for asthma is complete; a New Drug Application (NDA) submission is slated for the first half of 2026.
Strategic Implications
- Market Penetration – The partnership gives Chance a clear entry path into China’s largest respiratory‑disease market, while Huadong gains a differentiated inhaler to bolster its product portfolio.
- Regulatory Advantage – With Chance holding the MAH status, the product can secure a streamlined regulatory pathway under China’s New Drug Approval system.
- Commercial Growth – The milestone payment structure aligns incentives for both parties to accelerate approval and market uptake, potentially translating into significant revenue upside.-Fineline Info & Tech
